A Study Of PF-06647263 In Patients With Advanced Solid Tumors

NCT02078752 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

60

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated due to a change in sponsor prioritization.

Conditions

Neoplasms
Triple-Negative Breast Cancer

Interventions

DRUG: PF-06647263
DRUG: PF-06647263

Sponsor

Pfizer